Amyotrophic Lateral Sclerosis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

Amyotrophic Lateral Sclerosis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 90+ key pharma and biotech companies are working on 100+ pipeline drugs in the Amyotrophic Lateral Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Amyotrophic Lateral Sclerosis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Market. 

The Amyotrophic Lateral Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Amyotrophic Lateral Sclerosis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Amyotrophic Lateral Sclerosis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Amyotrophic Lateral Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Amyotrophic Lateral Sclerosis Pipeline Analysis

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the Amyotrophic Lateral Sclerosis Therapeutic Segment @


Amyotrophic Lateral Sclerosis Therapeutics Landscape

There are approx. 90+ key companies developing therapies for Amyotrophic Lateral Sclerosis. Currently, Biogen is leading the therapeutics market with its Amyotrophic Lateral Sclerosis drug candidates in the most advanced stage of clinical development.

The Leading Players in the Amyotrophic Lateral Sclerosis Therapeutics Market Include:

AB Science, AbbVie, AI Therapeutics, Inc., AL-S Pharma, Alector Inc., Amylyx Pharmaceuticals, Annexon, Inc., Apellis Pharmaceuticals, Inc., Aquestive Therapeutics, Ashvattha Therapeutics, Inc., Avanir Pharmaceuticals (a subsidiary of Otsuka America), Biogen, Biohaven Pharmaceuticals, Brainstorm Cell Therapeutics, Calico Life Sciences LLC, Cellenkos, Clene Nanomedicine Biosciences, Corcept Therapeutics, Covis, Cytokinetics/Astellas Pharma, Denali Therapeutics Inc., DS Pharma/PTC Therapeutics, Eledon Pharmaceuticals, Ferrer Internacional S.A., Genuv Inc., Helixmith Co., Ltd., InFlectis BioScience, Ionis Pharmaceuticals, Kadimastem, Knopp Biosciences, MediciNova, Mitsubishi Tanabe Pharma Corporation, Molecular Partners, NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Prilenia Therapeutics, Procypra Therapeutics, QurAlis Corporation, Rapa Therapeutics LLC, Retrotope, Inc., Revalesio Corporation, Sanofi, PTC Therapeutics, Seelos Therapeutics, UCB Pharma/Ra Pharmaceuticals, Woolsey Pharmaceuticals, ZZ Biotech, LLC, and others.

Amyotrophic Lateral Sclerosis Emerging and Marketed Therapies Covered in the Report Include:

  • AIT-101 (LAM-002A) – AI Therapeutics

  • AMX0035: Amylyx Pharmaceuticals

  • ANX005: Annexon

  • Exservan: Aquestive Therapeutics

  • ION363: Ionis Pharmaceuticals

  • Masitinib: AB Sciences

  • Nuedexta: Avanir Pharmaceuticals

  • Pridopidine: Prilenia Therapeutics

  • Radicava: Mitsubishi Tanabe Pharma Corporation

  • RELYVRIO (AMX0035): Amylyx Pharmaceuticals

  • RNS60: Revalesio Corporation

  • Tiglutik/ Teglutik: ITF Pharma


  • Tofersen: Biogen/Ionis Pharmaceuticals

  • Verdiperstat: Biohaven

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Amyotrophic Lateral Sclerosis Current Treatment Patterns

4. Amyotrophic Lateral Sclerosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Amyotrophic Lateral Sclerosis Late Stage Products (Phase-III)

7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)

8. Amyotrophic Lateral Sclerosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Amyotrophic Lateral Sclerosis Discontinued Products

13. Amyotrophic Lateral Sclerosis Product Profiles

14. Key Companies in the Amyotrophic Lateral Sclerosis Market

15. Key Products in the Amyotrophic Lateral Sclerosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Amyotrophic Lateral Sclerosis Unmet Needs

18. Amyotrophic Lateral Sclerosis Future Perspectives

19. Amyotrophic Lateral Sclerosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Throat Cancer Market

“Throat Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Throat Cancer market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Throat Cancer market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States